{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PD-1&page=9", "query": { "condition": "PD-1", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 938, "total_pages": 94, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PD-1&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PD-1&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T06:15:56.489Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05481658", "title": "Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous Metastases" ], "interventions": [ { "name": "Diphencyprone (DPCP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nicholas Gulati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2022-10-06", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-10-26T06:15:56.489Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05481658" }, { "nct_id": "NCT04140526", "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Advanced Solid Tumor", "Metastatic Melanoma", "Metastatic Head and Neck Carcinoma", "Metastatic Renal Cell Carcinoma", "Metastatic Colorectal Cancer", "Sarcomas", "Metastatic Prostate Cancer", "Ovarian Cancer", "Small Cell Lung Cancer", "Metastatic Breast Cancer", "Pancreas Cancer", "Gastric Cancer", "Esophageal Cancer", "Gastroesophageal Junction Adenocarcinoma", "Cervical Cancer", "Adenoid Cystic Carcinoma", "Salivary Gland Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "ONC-392", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoC4, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 733, "start_date": "2020-09-16", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-26T06:15:56.489Z", "location_count": 33, "location_summary": "Springdale, Arkansas • Davis, California • Downey, California + 27 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Davis", "state": "California" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04140526" }, { "nct_id": "NCT04799249", "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "TNBC - Triple-Negative Breast Cancer", "Breast Cancer" ], "interventions": [ { "name": "Trilaciclib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "G1 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 194, "start_date": "2021-05-14", "completion_date": "2024-05-24", "has_results": false, "last_update_posted_date": "2024-08-01", "last_synced_at": "2026-10-26T06:15:56.489Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Clinton", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04799249" }, { "nct_id": "NCT05676749", "title": "C-TIL051 in Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Non Small Cell Lung Cancer" ], "interventions": [ { "name": "C-TIL051", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AbelZeta Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2024-02-29", "completion_date": "2025-12-30", "has_results": false, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-10-26T06:15:56.489Z", "location_count": 3, "location_summary": "New Orleans, Louisiana • Raleigh, North Carolina • Pittsburgh, Pennsylvania", "locations": [ { "city": "New Orleans", "state": "Louisiana" }, { "city": "Raleigh", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05676749" }, { "nct_id": "NCT04704219", "title": "Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 160, "start_date": "2021-02-23", "completion_date": "2025-10-21", "has_results": true, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-10-26T06:15:56.489Z", "location_count": 8, "location_summary": "Washington D.C., District of Columbia • Billings, Montana • Las Vegas, Nevada + 5 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Billings", "state": "Montana" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04704219" }, { "nct_id": "NCT05060432", "title": "Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Lung Cancer", "Head and Neck Cancer", "Melanoma" ], "interventions": [ { "name": "EOS-448", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "inupadenant", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "SOC chemotherapies", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "iTeos Belgium SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2021-09-06", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2024-06-21", "last_synced_at": "2026-10-26T06:15:56.489Z", "location_count": 2, "location_summary": "San Diego, California • Bergen, New Jersey", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Bergen", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05060432" }, { "nct_id": "NCT06710847", "title": "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms, Colorectal", "Solid Tumor", "Colon Cancer", "Rectal Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "GSK4418959", "type": "DRUG" }, { "name": "PD-1 inhibitor", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2024-12-13", "completion_date": "2026-06-22", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-10-26T06:15:56.489Z", "location_count": 6, "location_summary": "Los Angeles, California • Denver, Colorado • Detroit, Michigan + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06710847" }, { "nct_id": "NCT03767348", "title": "Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)", "Microsatellite Instability-High (MSI-H)", "Non-melanoma Skin Cancer (NMSC)", "Cutaneous Melanoma" ], "interventions": [ { "name": "RP1", "type": "BIOLOGICAL" }, { "name": "nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Replimune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2017-09-20", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-26T06:15:56.489Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03767348" }, { "nct_id": "NCT02936752", "title": "Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2017-06-23", "completion_date": "2025-02-12", "has_results": true, "last_update_posted_date": "2025-03-25", "last_synced_at": "2026-10-26T06:15:56.489Z", "location_count": 19, "location_summary": "New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 13 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02936752" }, { "nct_id": "NCT05216835", "title": "Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Classical Hodgkin Lymphoma" ], "interventions": [ { "name": "Sabestomig (AZD7789)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "16 Years to 101 Years" }, "enrollment_count": 45, "start_date": "2022-03-18", "completion_date": "2025-09-04", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-10-26T06:15:56.489Z", "location_count": 5, "location_summary": "Duarte, California • Miami, Florida • Rochester, Minnesota + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05216835" } ] }